Castle Biosciences price target raised to $44 from $37 at Scotiabank
The Fly

Castle Biosciences price target raised to $44 from $37 at Scotiabank

Scotiabank raised the firm’s price target on Castle Biosciences (CSTL) to $44 from $37 and keeps an Outperform rating on the shares. The company’s Q3 results beat consensus expectations and raised its FY24 revenue guidance again, the analyst tells investors. TissueCypher ramp continues to outpace the firm’s expectations and the company is also on target to provide an update for its inflammatory disease pipeline by the end of 2024, the firm adds.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App